Other Events ·
Presents ATH434 Phase 2 data showing 52% slowing of functional decline in MSA
ATHEAlterity Therapeutics Ltd
Alterity Therapeutics presented new analyses from its randomized, double-blind, placebo-controlled ATH434-201 Phase 2 trial in Multiple System Atrophy (MSA) at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. After adjusting for baseline disease severity using cerebrospinal fluid neurofilament light chain (CSF NfL), ATH434 50 mg significantly slowed functional decline on the 11-item UMSARS Part I by approximately 52% versus placebo at Week 52, with a -4.64-point difference compared to placebo. The analysis also demonstrated that higher baseline CSF NfL predicts greater clinical decline, supporting its use as a severity covariate in future trials. Brain iron MRI imaging results were consistent with the drug's mechanism of action as an iron chaperone, although the primary endpoint for substantia nigra iron change was not met. Alterity Therapeutics is a biotechnology company developing disease-modifying treatments for neurodegenerative diseases.